Evidence map›Paper›PMID 42321264›Full record

ArticleScientific reports2026

Cervicovaginal microbiome diversity was not associated with mucosal pharmacokinetics of systemically delivered HIV broadly neutralizing antibodies.

Andile Mtshali, Amadou Hamidou Togo, Asavela Kama, Marothi Letsoalo, Gugulethu Mzobe, Aida Sivro, Nigel Garrett, Nomusa Zondo, Sharana Mahomed, Derseree Archary and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andile Mtshali *Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Amadou Hamidou Togo *Parasites & Microbes Research & Training Center Training Center (PMRTC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, Mali.
Asavela KamaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Marothi LetsoaloCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Gugulethu MzobeCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Aida SivroCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Nomusa ZondoCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Sharana MahomedCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Sinaye NgcapuCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. sinaye.ngcapu@caprisa.org.

Funding

European and Developing Countries Clinical Trials Partnership EDCTP Grant number: RIA2017SNational Research Foundation REF: TTK240315209308
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) are a promising HIV prevention strategy due to their potent antiviral activity and potential for long-acting protection. While the vaginal microbiome can influence mucosal immunity and the efficacy of topical interventions, its effect on the pharmacokinetics of systemically administered bNAbs remains unclear. Forty-two women were included in a retrospective analysis of the CAPRISA 012B clinical trial evaluating passive immunization for HIV prevention. Vaginal microbiota were profiled using 16 S rRNA gene sequencing and classified into three community state types (CSTs): CST I (Lactobacillus crispatus-dominated), CST III (Lactobacillus iners-dominated), and CST IV (diverse, non-Lactobacillus-dominated). Mucosal concentrations of CAP256V2LS were measured from Soft-cup

Indexed as

Broadly Neutralizing AntibodiesCervix UteriHIV AntibodiesHIV InfectionsMicrobiotaVaginaAdultFemaleHumansImmunity, MucosalLactobacillusMucous MembraneRetrospective StudiesRNA, Ribosomal, 16SBroadly Neutralizing AntibodiesHIV AntibodiesRNA, Ribosomal, 16SBroadly neutralizing antibodiesVaginal microbiomeWomen

Identifiers

PMID42321264
PMCPMC13554158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.